Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

633 PMBCL patients studied: key insights on refractory disease and survival

NCT ID NCT05162170

Knowledge-focused Sponsor: Fondazione Italiana Linfomi - ETS Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked back at 633 people with primary mediastinal large B-cell lymphoma (PMBCL) treated in Italy between 2007 and 2019. Researchers collected data on how well treatments worked, how many patients had disease that didn't respond or came back early, and survival rates. They also tracked side effects like heart problems and second cancers. Because this is a review of past records, it doesn't test a new treatment but helps understand real-world outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

633 people

The number who actually took part.

Started

Oct 2019

Finished

Jul 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients newly diagnosed with PMBCL between 01 January 2007 and 31 December 2019 attending participating centres.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * All consecutive patients treated in the centre during the period considered * Age\>=18 years * Histological diagnosis of PMBCL * Signature of "Informed Consent" to participate in the study (if applicable) * Treatment according to local practice * Diagnosis between 01 January 2007 and 31 December 2019 Exclusion Criteria: \- The exclusion criteria, being an observational study, are focused and limited to excluding cases with a non-compliant histological diagnosis.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Primary mediastinal large B-cell lymphoma (PMBCL) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

primary mediastinal large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Primary mediastinal large B-cell lymphoma (PMBCL)

Contacts and locations

Locations

  • Arnas Nuovo Ospedale Garibaldi Nesima

    Catania, 95122, Italy

  • Azienda Ospedaliera S.Giuseppe Moscati - S.C. Ematologia e Trapianto emopoietico

    Avellino, 83100, Italy

  • Azienda Ospedaliera Santa Maria - S.C. Oncoematologia

    Terni, 05100, Italy

  • Azienda Ospedaliera Universitaria Pisana - U.O. Ematologia

    Pisa, 56126, Italy

  • Clinica di Ematologia, AOU Ospedali Riuniti

    Ancona, 60126, Italy

  • Divisione Ematoncologia, IEO Istitito Europeo di Oncologia

    Milan, 20141, Italy

  • Divisione di Ematologia, A.O. Ospedali Riuniti Villa Sofia-Cervello

    Palermo, 90146, Italy

  • Divisione di Oncologia e dei Tumori immuno-correlati, IRCCS Centro di Riferimento Oncologico di Aviano

    Aviano, 33081, Italy

  • Ematologia Universitaria, A.O.U. Citta della Salute e della Scienza di Torino

    Torino, 10126, Italy

  • Ematologia, AOU Policlinico Giaccone

    Palermo, 90127, Italy

  • Ematologia, ASST Spedali Civili di Brescia

    Brescia, 25123, Italy

  • Ematologia, Azienda Ospedaliero - Universitaria Policlinico - Vittorio Emanuele Presidio Ospedale Ferrarotto

    Catania, 95124, Italy

  • Ematologia, Azienda Unitа Sanitaria Locale-IRCCS - Arcispedale Santa Maria Nuova

    Reggio Emilia, 42123, Italy

  • Ematologia, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano

    Milan, 20133, Italy

  • Ematologia, Grande Ospedale Metropolitano Bianchi Melacrino Morelli

    Reggio Calabria, 89124, Italy

  • Ematologia, Ospedale "Monsignor Raffaele Dimiccoli"

    Barletta, 76121, Italy

  • Ematologia, Ospedale Madonna delle Grazie

    Matera, 75100, Italy

  • Ematologia, Ospedale S. Camillo

    Roma, 00152, Italy

  • Ematologia, Ospedale Vito Fazzi

    Lecce, 73100, Italy

  • Ematologia, Universitа Cattolica S. Cuore

    Roma, 00168, Italy

  • Istituto Ematologia -Dipartimento di Medicina Traslazionale e di Precisione,Policlinico Umberto I - Universitа "La Sapienza"

    Roma, 00161, Italy

  • Istituto Oncologico Veneto I.R.C.C.S.

    Padova, 35128, Italy

  • Istituto di Ematologia "Seragnoli", Policlinico S.Orsola-Malpighi

    Bologna, 40138, Italy

  • Oncoematologia e TMO Dip. Oncologia, Casa di Cura La Maddalena

    Palermo, 90146, Italy

  • SC Ematologia e CTMO, Ospedale Businco

    Cagliari, 09121, Italy

  • SC Ematologia, A.O. SS. Antonio e Biagio e Cesare Arrigo

    Alessandria, 15121, Italy

  • SC Ematologia, A.O.U. Citta della Salute e della Scienza di Torino

    Torino, 10126, Italy

  • SC Ematologia, ASST Grande Ospedale Metropolitano Niguarda

    Milan, 20162, Italy

  • SC Ematologia, Azienda Ospedali Riuniti Papardo-Piemonte

    Messina, 98158, Italy

  • SC Ematologia, Ospedale "S.G. Moscati"

    Taranto, 74010, Italy

  • U.F. Oncoematologia, IOM (Istituto Oncologico del Mediterraneo)

    Viagrande, Catania, 95029, Italy

  • U.O. Ematologia con Trapianto, AOU Policlinico Consorziale

    Bari, 70124, Italy

  • U.O. Ematologia e Trapianti di Midollo, Ospedale Antonio Perrino

    Brindisi, 72100, Italy

  • U.O.C. Ematologia - IRCCS Istituto Tumori Giovanni Paolo II

    Bari, 70124, Italy

  • UO Ematologia, AOU Integrata di Verona

    Verona, 37134, Italy

  • UO Ematologia, Casa Sollievo della Sofferenza

    San Giovanni Rotondo, 71013, Italy

  • UO Ematologia, Istituto Clinico Humanitas

    Rozzano, 20089, Italy

  • UOC Ematologia Oncologica, Istituto Nazionale Tumori - IRCCS Fondazione G. Pascale

    Naples, 80131, Italy

  • UOC Ematologia, Azienda Ospedaliera di Cosenza

    Cosenza, 87100, Italy

  • Unitа funzionale di Ematologia, Azienda Ospedaliera Universitaria Careggi

    Florence, 50141, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.